SCHEDULE: BlackRock Amends Cogent Biosciences Stake to 6.5%

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 6.5% beneficial ownership stake in Cogent Biosciences, Inc. as of December 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 11,370,224 shares of Cogent Biosciences, Inc. common stock.
• This represents 6.5% of the class of securities.
• BlackRock holds sole voting power over 11,135,084 shares and sole dispositive power over 11,370,224 shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported stake.
• BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cogent Biosciences, Inc.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership disclosure (Schedule 13G/A) by a large institutional investor, BlackRock, Inc. It indicates a passive stake and does not contain information that would inherently suggest a positive or negative sentiment regarding the issuer's performance or future prospects. The 6.5% stake is significant but typical for institutional holdings.

Positives

• BlackRock, a major institutional investor, maintains a significant 6.5% stake in Cogent Biosciences, Inc., which can be viewed as a vote of confidence in the company.

Future Outlook

This filing is a beneficial ownership disclosure and does not contain forward-looking statements or guidance from Cogent Biosciences, Inc.

Management Comments

• "I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing indicates that Cogent Biosciences, Inc. continues to be a holding within BlackRock's investment portfolios. Schedule 13G filings are routine disclosures by institutional investors holding more than 5% of a company's stock, signifying a passive investment intent rather than an aim to influence management or control.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially offering some stability or validation.
• Management: Confirms a large passive institutional investor, which typically does not seek to influence corporate control.

Key Dates

Keywords

BlackRock, Cogent Biosciences, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Equity Stake